OSE Immunotherapeutics SA OSE
EURONEXT · France · Health Technology
€2.17-0.07 (-2.95%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
€11.1 million cash position as of June 30, 2026; cash runway confirmed through December 2026The Company continues to engage actively with institutional investors in the United States and Europe to extend its cash runway beyond key upcoming value inflection pointsIn this context, publication of first half 2026 financial results is postponedEnrolment of Tedopi’s Phase 3 clinical trial ARTEMIA in lung cancer on track for completion by end of December 2026; planned futility analysis now estimated fo
Nantes, France, September 23, 2026 – 7:30am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that topline results from the Combi-TED Phase 2 international clinical trial of Tedopi® in metastatic Non-Small Cell Lung Cancer sponsored by FoRT have been selected for an oral presentation at the 2026 Annual Meeting of the European Society for Me
Nantes, France, September 9, 2026 – 6pm CEST – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (the “Company”) welcomes the announcement by its licensee Veloxis Pharmaceuticals, Inc. that the first patient has been dosed in RENGEVITY-201, a Phase 2 clinical trial evaluating pegrizeprument (VEL-101) for the prevention of organ rejection in kidney transplant recipients. Pegrizeprument (also known as VEL-101) is a novel investigational immunomodulatory monoclonal monovalent antibody frag
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.